Use of Incretins in Diabetic Patients
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: DPP-4 inhibitors
- Registration Number
- NCT03486964
- Lead Sponsor
- University of Pavia
- Brief Summary
Observational, retrospective study, conducted in diabetic patients aimed to evaluate the effects on the glyco-metabolic control and on cardiovascular events of different DPP-4 inhibitors. Patients will be stratified in patients taking different DPP-4 in addition to sulfonylureas, biguanides, thiazolidinediones, insulin, compared to those in therapy with other hypoglycemic classes, such as sulphonylureas, biguanides, thiazolidinediones, insulin, alone or in combination, in primary and secondary prevention.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2234
Inclusion Criteria
- Type 2 diabetic patients
- On oral hypoglycemic agents ± basal insulin
- In primary and secondary prevention
Exclusion Criteria
- Patients with a follow-up of less than 8 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description DPP-4 plus other therapies DPP-4 inhibitors Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
- Primary Outcome Measures
Name Time Method Post-prandial plasma glucose 8 years mg/dl
Fasting plasma glucose 8 years mg/dl
Glycated hemoglobin 8 years Percentage
- Secondary Outcome Measures
Name Time Method Fatal myocardial infarction 8 years Percentage
Atrial fibrillation 8 years Percentage
Cardiovascular death 8 years Percentage
Angina pectoris 8 years Percentage
Extrasystoles 8 years Percentage
Non-fatal myocardial infarction 8 years Percentage
Heart failure 8 years Percentage
Trial Locations
- Locations (1)
IRCCS Policlinico San Matteo Foundation
🇮🇹Pavia, Lombardy, Italy